Insights for Health Plans

Below is an excerpt from an article by AlignRx chief pharmacy officer Beckie Fenrick and Goodroot area vice president of business development Brian Shonat that was recently published in BenefitsPRO. Following decades of patent litigation and maneuvering, the first biosimilar to Humira is now available with many more to follow this year. Humira is a …

What Brokers and TPAs Need To Know About Humira Biosimilars Read More »

A new trend in insulin pricing? Here’s what you need to know. Insulin pricing has been a topic of concern and debate in recent years, as prices have skyrocketed, making it difficult for many patients with diabetes to afford the medication they need. However, the following recent announcements from major pharmaceutical manufacturers—who make up about …

A Shake Up in the U.S. Insulin Market: Major Manufacturers Lower Insulin Costs Read More »

The industry report you’ve been waiting for. Today biosimilars seem to be the topic of conversation everywhere. Why? Humira. The launch of Humira biosimilars will be a test for industry stakeholders, as their entrance will reveal whether blockbuster drugs—that offer significant rebates—can be replaced to reduce the cost burden on patients and payers in the United States. Download our …

Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars Read More »